ECONOMIC EVALUATION OF THROMBO INCODE, A GENETIC PLATFORM FOR THE ASSESSMENT OF VENOUS THROMBOEMBOLISM (VTE) RISK IN PATIENTS WITH A PATTERN OF VTE OR A CONDITION THAT SUGGESTS A HEREDITARY COMPONENT
Author(s)
Marrugat J1, Elosúa R1, Coca A2, de la Figuera M3, Rubio-Terrés C4, Rubio-Rodríguez D5, Ramírez de Arellano A6, Boldeanu A6, Puig-Gilberte J7, Salas E71IMIM-Hospital del Mar, Barcelona, Spain, 2Hospital Clínic, Barcelona, Spain, 3CAP Cerdenya, Barcelona, Spain, 4HealthValue, Madrid, Spain, 5Health Value, Madrid, Spain, 6FERRER-inCode, Barcelona, Spain, 7GENDIAG, Barcelona, Spain
OBJECTIVES: To conduct an economic analysis of the risk assessment of VTE with Thrombo inCode, a genetic platform, in patients with a pattern of VTE or a condition that suggests a hereditary component, compared with the standard methods so far used (Factor V Leiden and prothrombin G20210A mutation). METHODS: A Markov model was developed with 7 states of health (thrombophilia, no thrombophilia, VTE, major bleeding, intracranial hemorrhage, no intracranial hemorrhage, and death). The predictive ability of VTE from the identification of thrombophilia with Thrombo inCode and the standard method, was obtained from three studies of the method validation performed in three different populations (3,661 patients in total). It was assumed that patients with thrombophilia positively identified undergo a preventive treatment of VTE, which involves both reducing the number of VTE as the increase in major bleeding. The utilities and costs of Markov states were obtained from the literature and Spanish sources. The analysis was done from the National Health System perspective, for a time horizon of 5 years and lifetime. An annual discount rate of 3.5% for costs and benefits was applied. RESULTS: For a Thrombo inCode price of 290 €, this genetic platform would be the dominant option for any time horizon from 5 years. The threshold price of Thrombo inCode to reach the incremental cost-effectiveness ratio (ICER) threshold generally accepted in Spain (30,000 €/QALY) would range between € 1,069 and € 1,284. Probabilistic analyses indicate that Thrombo inCode assessment is dominant in the 97.2 to 98.6% of the tests, according to the selected population. CONCLUSIONS: Thrombo inCode is a cost-effective genetic option in VTE risk assessment compared with the standard method.
Conference/Value in Health Info
2012-11, ISPOR Europe 2012, Berlin, Germany
Value in Health, Vol. 15, No. 7 (November 2012)
Code
PCV69
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Cardiovascular Disorders, Respiratory-Related Disorders